This week, eight biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Trillium Therapeutics Inc. (TRIL) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. In Portfolio Grader’s specific subcategory of Earnings Momentum, TRIL also gets an A. For more information, get Portfolio Grader’s complete analysis of TRIL stock.
ArQule, Inc. (ARQL) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. ArQule is a biotechnology company that is engaged in the research and development of cancer therapeutics. For more information, get Portfolio Grader’s complete analysis of ARQL stock.
La Jolla Pharmaceutical Company’s (LJPC) ratings are looking better this week, moving up to an A from last week’s B. For more information, get Portfolio Grader’s complete analysis of LJPC stock.
Incyte Corporation (INCY) is seeing ratings go up from a C last week to a B this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.
This week, Ambit Biosciences Corp. (AMBI) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
This week, Progenics Pharmaceuticals, Inc.’s (PGNX) ratings are up from a C last week to a B. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
The rating of Celladon Corporation (CLDN) moves up this week, rising from a B to an A. For more information, get Portfolio Grader’s complete analysis of CLDN stock.
Lion Biotechnologies, Inc. (LBIO) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of LBIO stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
